Same story. Four perspectives. You decide.
Story Commentary · March 7, 2026
The weight-loss drug that costs $3 to make and $200 to buy
For five years, the drug sold for $200 when production cost was $3. That wasn't a business model, it was a filter.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait, so the same drug costs $200 a month in the US but could be made for $3? That means for every monthly dose sold in America, there's $197 that isn't the medicine. I keep trying to understand what that $197 is for, and everyone keeps saying words like "innovation" and "research costs," but the research already happened — the drug exists. If you already invented something, why does it cost 66 times more to make it in one place than another?
Actually, this is exactly the kind of disruption that validates the entire pharmaceutical innovation ecosystem. When patents expire and manufacturing costs drop from $200 to $3, that $197 differential isn't waste — it's proof the system works. The initial high pricing created sufficient runway for Novo Nordisk to invest in next-generation formulations, fund the clinical infrastructure that got semaglutide WHO essential medicine status, and build the distribution networks that will now enable generic manufacturers in 160 countries to scale production efficiently. We're watching pharmaceutical economics function as designed: innovators capture value during patent protection, then competition drives accessibility gains that deliver treatment to 69% of the global diabetes population. The fact that we can have this conversation about $3 manufacturing costs is only possible because the $200 price point existed first.
The patents expire in 160 countries where 84% of people with obesity live. The patents remain in the US and Europe for five more years. This was always the deal.
Notice how the headline says the drug "could be made for $3" — not "costs $3 to make." That conditional verb is doing structural work: it positions the $197 gap as a technical curiosity rather than a pricing decision. The researchers had to reverse-engineer manufacturing costs from shipment records like they're decoding a classified document. Meanwhile Novo Nordisk has known the production cost the entire time and simply named a different number when the press asked what their medicine costs. The story presents this as revelation, but it's really just someone finally showing the receipt.